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Introduction: The kinetoplastid protozoan parasites of the genus Leishmania cause 
diseases for which treatment is difficult and there is still no vaccine for use in 
humans. Leishmanolysin is the major enzymatic protein component of the 
promastigote surface. Because of its role as a ligand involved in the interaction of 
the parasite with defensive systems of the host, including components of the 
complement system and the macrophage surface is an attractive candidate for 
designing peptide vaccines. 
 
Methods and Results: In the current study, PEPOP was used to predict peptides 
from Leishmanolysin in the form of discontinuous B-cell epitopes. PEPOP identified 
segments comprised of accessible and sequence continuous amino acids. These 
segments were clustered according to their spatial distances using method of 
extensions: Optimized Nearest Neighbor (ONN), Optimized Flanking Nearest 
Neighbor (OFN), Optimized Patched segments Path (OPP), Traveling Salesman 
Problem (TSP), and Shortest Path (SHP). Each peptide sequence has been generally 
comprised of several segments. From 3D structure of Leishmanolysin, PEPOP 
identified 100 segments gathered in three clusters according to their spatial 
distances. In this study, we wanted to predict peptides from a specific region of the 
protein, the residue 264-345 on the active site of Leishmanolysin. It corresponds to 
the segments S34 to S48. The predicted peptides, which did not relate to this region 
(264-345) were removed and at last 29 peptides were selected. 
Conclusions: 
These results using bioinformatics analyses could be conducted in vaccine design 
against Leishmania infections. 
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